Australia markets closed

Ion Beam Applications SA (IOBCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
21.45-0.45 (-2.05%)
At close: 2:33PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close21.90
Open21.45
Bid0.00 x 0
Ask0.00 x 0
Day's range21.45 - 21.45
52-week range8.15 - 21.90
Volume605
Avg. volume130
Market cap612.758M
Beta (5Y monthly)0.61
PE ratio (TTM)16.50
EPS (TTM)1.30
Earnings dateN/A
Forward dividend & yield0.09 (0.40%)
Ex-dividend date29 June 2020
1y target estN/A
  • IBA – TRANSPARENCY NOTIFICATION
    GlobeNewswire

    IBA – TRANSPARENCY NOTIFICATION

    Louvain-la-Neuve, Belgium, June 8 th, 2021, 17.45 Summary of the notificationIBA (Ion Beam Application), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on June 7th, 2020. In its notification, Ion Beam Applications SA has notified, that following an acquis

  • Iba – Acquisition of Own Shares Completion of the Share Buyback Program
    GlobeNewswire

    Iba – Acquisition of Own Shares Completion of the Share Buyback Program

    Immediate Release – May 27th, 2021 Louvain-la-Neuve, Belgium, May 27th, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on January 12th, 2021. Under this program, IBA has requested a financial intermediary to repurchase up to 357.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until May 31st, 2021, effective as from January 13th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel. In the framework of this share buyback program, IBA repurchased 22.384 IBA shares on Euronext Brussels in the period from May 14th, 2021 up to and including May 20th, 2021, as follows: These transactions include the purchase of a block of 4.000 shares at a price of 17,30 EUR/share, which was executed on May 20th, 2021 at 10.01 AM on the central order book of Euronext Brussels (XBRU). The total number of shares purchased under this program therefore amounts to the target of 357.000, which terminates the program, at an average price of 15,4576 EUR/share. As a result, IBA SA currently holds 831.221 treasury shares (directly and indirectly through its subsidiary IBA Investments SCRL), representing 2,76% of its share capital. About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com Contact person IBA Christian Matton,Chief Legal Officershareholderrelations@iba-group.com Attachment 20210527_iba_share_buy_back_en (2)

  • IBA Press Release: IBA Business Update – First Quarter 2021
    GlobeNewswire

    IBA Press Release: IBA Business Update – First Quarter 2021

    Louvain-La-Neuve, Belgium, 20 May 2021 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its business update for the first quarter ending 31 March 2021. Group Overview Strong balance sheet maintained, with EUR 152 million unaudited gross cash (31 Dec 2020: EUR 151.3 million) and EUR 72.6 million unaudited net cash (31 Dec 2020: EUR 65.2 million)Business operations have remained solid into the first quarter of 2021, albeit with some continuing impact from COVID-19 related installation delays in Proton Therapy alongside some Other Accelerator delays Continued focus on sustainable growth and profitability, delivering the very best offering and services to our customers, whilst remaining committed to corporate responsibility As part of a long-term employee incentive plan, IBA’s share buyback program was launched in January 2021 and is almost complete Olivier Legrain, Chief Executive Officer of IBA commented: “I have been pleased to see IBA’s continued resilience in the first quarter of 2021, with growing momentum in Proton Therapy in the US, continued success in Asia and strong performance in our Dosimetry and Other Accelerators businesses.” “Our roadmap to sustainable growth and profitability is clear: capitalize on our market leading position globally, invest for strategic impact and deliver operational execution. This focus will be reinforced by our continuing commitment to our customers, our employees and to the planet and I am proud of the groundwork we are laying as a company towards a true stakeholder approach to our business.” Business Unit Highlights (including post-period end) Proton Therapy Strong pipeline in both the US and the Asia-Pacific region with installation of one Proteus®ONE* system commencing in the first quarter 37 service contracts generating recurring revenues globallyDown payment received for a Proteus®ONE from the National Cancer Center (NCC) Korea, a repeat customerPost-period end, Advocate Radiation Oncology selected IBA’s Proteus®ONE for its new Radiation Oncology Centre. A term sheet has been signed and contract negotiations are currently ongoingYves Jongen, IBA’s founder, received the Lifetime Achievement Award from the American National Association for Proton Therapy (NAPT). This prestigious title recognizes his pioneering work and his exceptional contribution, spanning over 35 years, to the innovation and clinical development of proton therapy Other Accelerators (RadioPharma, Industrial) Interest has continued to build in IBA’s high energy machines Other Accelerators performed well in the first quarter, with seven machines sold in the year to date, across Asia, Africa, South America and Europe Dosimetry Revenues and order intake remain strongOffering boosted by launch of a range of new quality assurance products: myQA® SRS, MatriXX Resolution, as well as myQA® Phoenix, the unique high-resolution digital detector array for proton therapy commissioning Outlook During the first quarter, IBA’s performance has been resilient, with strong performance across all business units. The robust balance sheet and stability of service revenues provide a strong basis for our performance in 2021 and beyond. COVID-19 continues to be a source of uncertainty both in the speed of installations, and in terms of future performance. For the time being IBA remains unable to provide reliable guidance, but intends to provide more detailed projections as soon as possible. Shareholder's AgendaAnnual Shareholders’ Meeting Wednesday, June 9, 2021First Half 2021 Results Wednesday, August 25, 2021 Third Quarter 2021 Business Update Thursday, November 18, 2021 Directors' Declarations In accordance with the Royal Decree of 14 November 2007, IBA indicates that this Trading Update has been prepared by the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO). About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com *Proteus®ONE is a brand name of Proteus 235 CONTACTSSoumya ChandramouliChief Financial Officer+32 10 475 890Investorrelations@iba-group.com Olivier LechienCorporate Communication Director+32 10 475 890communication@iba-group.com Consilium Strategic CommunicationsAmber Fennell, Angela Gray, Lucy Featherstone+44 (0) 20 3709 5700IBA@consilium-comms.com Attachment 210520-IBA-Q1-update_EN-b